Explore
Upload

DocSlides is a free service to upload presentations and documents.

Upload Now

Search Results for 'Dapt Rivaroxaban'

Dapt Rivaroxaban published presentations and documents on DocSlides.

A ssessment of D ual antiplatelet therapy versus

A ssessment of D ual antiplatelet therapy versus

  • stefany-barnette
  • 22 Slides

A ssessment of D ual antiplatelet therapy versus...

A ssessment of D ual antiplatelet therapy versus

A ssessment of D ual antiplatelet therapy versus

  • coursion
  • 22 Slides

R. ivaroxaban . I. n atrial . F. ibrillation patie...

Dual Antiplatelet Therapy (DAPT) Duration

Dual Antiplatelet Therapy (DAPT) Duration

  • tatiana-dople
  • 0 Slides

Dilemma: Recent Trials And Guidelines For. Clinic...

Rivaroxaban compared with enoxaparin for the prevention of

Rivaroxaban compared with enoxaparin for the prevention of

  • luanne-stotts
  • 21 Slides

Alexander T Cohen . On behalf of the MAGELLAN Ste...

Rivaroxaban or Aspirin for Extended Treatment of Venous Thr

Rivaroxaban or Aspirin for Extended Treatment of Venous Thr

  • yoshiko-marsland
  • 25 Slides

(EINSTEIN CHOICE). Ryan Sparks, . PharmD. , BCPS....

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

A Multicenter Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban

  • celsa-spraggs
  • 0 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:

Rivaroxaban Plus Aspirin in Patients With and Without Heart Failure and Chronic Coronary or Peripheral Artery Disease:

  • giovanna-bartolotta
  • 15 Slides

Rivaroxaban Plus Aspirin in Patients With and Wit...

Sangramento GI associado a PCI

Sangramento GI associado a PCI

  • marina-yarberry
  • 22 Slides

Juan Felipe Castillo Schrul. Residente Hemodinâm...

What Has Been Tried and What Is True?

What Has Been Tried and What Is True?

  • celsa-spraggs
  • 0 Slides

What Has Changed?. Less Stent Thrombosis . With. ...

Evidence-Based Antiplatelet Therapy Across the ACS Spectrum

Evidence-Based Antiplatelet Therapy Across the ACS Spectrum

  • debby-jeon
  • 42 Slides

Evidence-Based Antiplatelet Therapy Across the AC...

DUAL ANTIPLATELET THERAPY

DUAL ANTIPLATELET THERAPY

  • mary
  • 36 Slides

(DAPT) . BHAVI SHAH, DNP, APRN, ANP-C. UNIVERSITY ...

Dominick J. Angiolillo

Dominick J. Angiolillo

  • SunnySeahorse
  • 37 Slides

, MD. , PhD. Professor. of Medicine. Medical Dire...

Aspirin in 2022: A New Aspirin for a New Chapter

Aspirin in 2022: A New Aspirin for a New Chapter

  • belinda
  • 47 Slides

March 28, 2022. Disclosures. Present Research/Gran...

Switching from dual antiplatelet therapy with aspirin plus a P2Y

Switching from dual antiplatelet therapy with aspirin plus a P2Y

  • brown
  • 16 Slides

12. inhibitor to dual pathway inhibition with asp...

Recent ACS: STEMI, NSTEMI, UA

Recent ACS: STEMI, NSTEMI, UA

  • danika-pritchard
  • 20 Slides

Stabilized 1-7 Days Post-Index Event. Exclusions:...

A New Era in Anticoagulation Management

A New Era in Anticoagulation Management

  • debby-jeon
  • 46 Slides

Allyson Sarigianis, Pharm.D.. October 19, 2013. O...

Novel Oral Anticoagulants

Novel Oral Anticoagulants

  • natalia-silvester
  • 88 Slides

(. N. OAC). Dan . Moellentin. , . PharmD. , BCPS,...

A Multicenter Randomized Trial Evaluating Clinically Signif

A Multicenter Randomized Trial Evaluating Clinically Signif

  • ellena-manuel
  • 20 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

R eal-world

R eal-world

  • liane-varnes
  • 20 Slides

EVI. dence. on . S. troke prevention . I. n pati...

New Oral Anticoagulant

New Oral Anticoagulant

  • mitsue-stanley
  • 80 Slides

R2 Patcharee Seesongsom. R2 . Sirada. . Phoja...

A Multicenter Randomized Trial Evaluating Clinically Signif

A Multicenter Randomized Trial Evaluating Clinically Signif

  • giovanna-bartolotta
  • 20 Slides

Magnus Ohman MB, on behalf of the GEMINI-ACS-1 In...

Stroke, Bleeding, and

Stroke, Bleeding, and

  • lois-ondreau
  • 7 Slides

Mortality Risks . in . Elderly Medicare Beneficia...

A New Era in Anticoagulation Management

A New Era in Anticoagulation Management

  • alexa-scheidler
  • 0 Slides

Allyson Sarigianis, Pharm.D.. October 19, 2013. O...

CAD/PAD in Primary Care CV Risk in Stable Outpatients

CAD/PAD in Primary Care CV Risk in Stable Outpatients

  • stefany-barnette
  • 0 Slides

Stratified by Baseline CV Risk Category. Aspirin ...

Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators

Dr. Phil Wells on behalf of the EINSTEIN CHOICE Steering Committee and Investigators

  • yoshiko-marsland
  • 18 Slides

Dr. Phil Wells on behalf of the EINSTEIN CHOICE ...

Ima A. Kusuma , MD, FIHA

Ima A. Kusuma , MD, FIHA

  • hirook
  • 33 Slides

“JIH. ” Hospital, Yogyakarta, Indonesia. The U...

Rivaroxaban in stable peripheral or carotid artery disease

Rivaroxaban in stable peripheral or carotid artery disease

  • basidell
  • 17 Slides

Sonia Anand, on . behalf of the COMPASS Steering C...

Thromboembolic protocols

Thromboembolic protocols

  • cecilia
  • 27 Slides

& safe anticoagulant prescribing. July 2020. D...

X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the

X- VeRT CV death, stroke/TIA, non-CNS systemic embolism, or MI: 0.51% of the

  • LittleMissPerfect
  • 1 Slides

rivaroxaban. group vs. 1.02% of the vitamin K ant...

MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,

MAGELLAN Primary efficacy endpoint at 10 days (DVT, symptomatic PE,

  • HoneyBun
  • 1 Slides

VTE death. ) for . rivaroxaban. vs. . enoxaparin....

Review on NOACs Studies Dr.

Review on NOACs Studies Dr.

  • BlessedBeyondMeasure
  • 37 Slides

Kourosh. . Sadeghi. Tehran University of medical ...

Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding

Reversing Course: Managing Anticoagulation and Antiplatelet Bleeding

  • kyle585
  • 20 Slides

Paul P. . Dobesh. , . Pharm.D. , FCCP, BCPS, BCCP....

Administrative

Administrative

  • phoebe-click
  • 47 Slides

. Principles. of . Vaccination. Prof. Dr. AHMET...

Two-Year Outcomes of

Two-Year Outcomes of

  • jane-oiler
  • 18 Slides

High Bleeding Risk Patients after Polymer-Free Dr...

Antiplatelet therapy in CAD

Antiplatelet therapy in CAD

  • alexa-scheidler
  • 0 Slides

Minilecture. Objectives. Indications for Antiplat...

Antiplatelet therapy in CAD

Antiplatelet therapy in CAD

  • celsa-spraggs
  • 0 Slides

Minilecture. Objectives. Indications for Antiplat...

September 18, 2018 Andrea Price, MS, CPHQ, RCIS, CCA

September 18, 2018 Andrea Price, MS, CPHQ, RCIS, CCA

  • celsa-spraggs
  • 41 Slides

September 18, 2018 Andrea Price, MS, CPHQ, RCIS, ...

Pieter Stella, MD, PhD On behalf of the ReCre8 Study investigators

Pieter Stella, MD, PhD On behalf of the ReCre8 Study investigators

  • serenemain
  • 26 Slides

ClinicalTrials.gov NCT02328898. A Permanent Polyme...

Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients

Expert Discussion on Antiplatelet for ACS Patients: Controversies for Asian Patients

  • GratefulHeart
  • 52 Slides

Akhtar . Fajar. . Muzakkir. New ESC NSTEMI Guidel...

SFA Intervention: In for a Penny

SFA Intervention: In for a Penny

  • hadley
  • 20 Slides

Michael N. Young, MD, RPVI. Dartmouth-Hitchcock He...

Copyright © 2024 DocSlides. All Rights Reserved